Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

1. Weisel, K.
2. Dimopoulos, M.
3. Moreau, P.
4. Yagci, M.
5. Larocca, A.
6. Kanate, A.S.
7. Vural, F.
8. Cascavilla, N.
9. Basu, S.
10. Johnson, P.
11. Byeff, P.
12. Hus, M.
13. Rodríguez-Otero, P.
14. Muelduer, E.
15. Anttila, P.
16. Hayden, P.J.
17. Krauth, M.-T.
18. Lucio, P.
19. Ben-Yehuda, D.
20. Mendeleeva, L.
21. Guo, S.
22. Yu, X.
23. Grote, L.
24. Biyukov, T.
25. Dhanasiri, S.
26. Richardson, P.
27. Alle Autoren anzeigen +